AAPG

Ascentage Pharma Group International (AAPG) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-08-01

Overall Score

Revenue Growth

Revenue growth remains the key missing ingredient for a 10-year growth case, with valuation still stretched at 19.8x EV/Sales despite no evidence of accelerating top-line momentum.

The business is still operating with very weak profitability, as TTM net margin is -216.7% and operating margin is -210.4%, which limits the ability to compound growth efficiently.

Profitability Margins

Gross margin is strong at 84.1%, but it is overwhelmed by negative EBIT margin (-210.4%) and negative EBITDA margin (-196.0%), indicating severe operating inefficiency.

Returns remain deeply negative, including ROA of -31.0%, ROE of -123.6%, and ROIC of -33.7%, which is inconsistent with durable long-term compounding.

Cash Flow Capital Efficiency

Free cash flow remains negative, with FCF yield at -10.6% and EV/FCF at -9.1x, showing the company is still burning cash rather than funding growth internally.

Capital efficiency is weak, with operating cash flow ratio at -0.74 and cash conversion cycle at -153.2 days, despite a strong current ratio of 1.79.

Balance Sheet Dilution

Liquidity is acceptable with a current ratio of 1.79 and cash ratio of 1.50, which provides some cushion for ongoing losses.

Net debt remains manageable at 0.44x EBITDA, but the company still carries meaningful leverage relative to its weak earnings power.

Reinvestment Growth Runway

R&D intensity is high at 196.6% of revenue, but the spending has not yet translated into positive operating leverage or sustainable returns.

Working capital is positive at $1.30B, but the long operating cycle and negative cash generation suggest reinvestment is not currently producing efficient growth.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →